Rho kinase as a therapeutic target in cardiovascular disease

Future Cardiology

Volumn 7, Issue 5, 2011, Pages 657-671

  Surma, Michelle ^a   Wei, Lei ^a   Shi, Jianjian ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

cardiovascular; disease; heart; inhibitor; Rho kinase; ROCK

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; FASUDIL; GSK 269962A; H 1152; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; PHOSPHATASE; RHO KINASE; RHO KINASE INHIBITOR; SAR 407899; SB 772077; SERUM RESPONSE FACTOR; TENSIN; UNCLASSIFIED DRUG;

APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CYTOSKELETON; DRUG TARGETING; ENZYME ACTIVITY; HEART CONTRACTION; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; AMIDES; APOPTOSIS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART FAILURE; HUMANS; MALE; MYOCYTES, CARDIAC; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PYRIDINES; RHO-ASSOCIATED KINASES; VASODILATION;

EID: 80053101752     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.11.51     Document Type: Review

References (199)

1. Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 15(9), 2208-2216 (1996). (Pubitemid 26141137)
2. Ishizaki T, Maekawa M, Fujisawa K, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J. 15(8), 1885-1893 (1996). (Pubitemid 26119224)
3. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lell. 392(2), 189-193 (1996). (Pubitemid 26276745)
4. Leung T, Chen XQ, Manser E, Lim L. The pl60 RhoA-binding kinase ROK a is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol. Cell. Biol. 16(10), 5313-5327 (1996). (Pubitemid 26315050)
5. Burridge K, Wcnncrbcrg K. Rho and Rac take ccnrcr stage. Cell 116(2), 167-179 (2004). (Pubitemid 38167310)
6. Hahmann G, Schroctcr T. Rho-kinasc inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell. Mol. Life Sci. 67(2), 171-177 (2010).
7. Loirand G, Pacaud P. The role of Rho protein signaling in hypertension. Nat. Rev. Cardiol. 7(11), 637-647 (2010).
8. Miyamoto S, Del Re DP, Xiang SY, Zhao X, Florholmcn G, Brown JH. Revisited and revised: is RhoA always a villain in cardiac pathophysiology? J. Cardiovas. Transl. Res. 3 (4), 330-343 (2010).
9. Nuncs KP, Rigsby GS, Webb RG. RhoA/Rho-kinasc and vascular diseases: what is the link? Cell. Mol. Life Sci. 67(22), 3823-3836 (2010).
10. Shi J, Wei L. Rho kinase in the regulation of cell death and survival. Arch. Immunol. Ther. Exp. (Warsz) 55(2), 61-75 (2007). (Pubitemid 46559196)
11. Dong M, Yan BP, Liao JK, Lam YY, Yip GW, Yu GM. Rho-kinasc inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov. Today 15(15-16), 622-629 (2010).
12. Amano M, Nakayama M, Kaibuchi K. Rho-kinasc/ROGK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken) 67(9), 545-554 (2010).
13. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinasc: important new therapeutic target in cardiovascular diseases. Am. J. Physiol. Heart Circ. Physiol. 301(2), H287-H296 (2011).
14. Zhou Q, Gensch G, Liao JK. Rho-associated coiled-coil-forming kinases (ROGKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol. Sci. 32(3), 167-173 (2011).
15. Gonnolly MJ, Aaronson PI. Key role of the RhoA/Rho kinase system in pulmonary hypertension. Pulm. Pharmacol. Ther. 24(1), 1-14 (2011).
16. Pinterova M, Kunes J, Zicha J. Altered neural and vascular mechanisms in hypertension. Physiol. Res. 60 (3), 381-402 (2011).
17. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinasc inhibitor (S)-(+)-2-mcthyl-l-[4-mcthyl-1-5-isoquinolinc)sulfonyl]-homopipcrazinc as a probing molecule for Rho-kinasc-involved pathway. Pharmacol. Ther. 93(2-3), 225-232 (2002). (Pubitemid 34615563)
18. Shibuya M, Hirai S, Scto M, Satoh S, Ohtomo E. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J. Neurol. Sci. 238(1-2), 31-39 (2005). (Pubitemid 41560951)
19. Suzuki Y, Shibuya M, Satoh S, Sugimoto Y, Takakura K. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg. Neurol. 68(2), 126-131 (2007). (Pubitemid 47087900)
20. Zhao J, Zhou D, Guo J, et al. Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. Neurol. Med. Chir. (Tokyo) 46(9), 421-428 (2006).
21. Uchata M, Ishizaki T, Satoh H, et al. Galcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389 (6654), 990-994 (1997). (Pubitemid 27485693)
22. Asano T, Ikcgaki I, Satoh S. et al. Mechanism of action of a novel antivasospasm drug, HA1077. J. Pharmacol. Exp. Ther. 241(3), 1033-1040 (1987).
23. Suzuki N, Hajicck N, Kozasa T. Regulation and physiological functions of G12/13-mcdiatcd signaling pathways. Neurosignals 17(1), 55-70 (2009).
24. Aittalcb M, Boguth GA, Tcsmcr JJ. Structure and function of hctcrotrimcric G protein-regulated Rho guanine nucleotide exchange factors. Mol. Pharmacol. 77(2), 111-125 (2010).
25. Fu X, Gong MG, Jia T, Somlyo AV, Somlyo AP. The effects of the Rho-kinasc inhibitor Y-27632 on arachidonic acid-, GTPγS-, and phorbol ester-induced Ga2+ -scnsitization of smooth muscle. FEBS Leu. 440(1-2), 183-187 (1998). (Pubitemid 28558761)
26. Feng J, Ito M, Kurcishi Y ,et al. Rho-associated kinase of chicken gizzard smooth muscle. J. Biol. Chem. 274(6), 3744-3752 (1999). (Pubitemid 29077222)
27. Shirao S, Kashiwagi S, Sato M, et al. Sphingosylphosphorylcholine is a novel messenger for r-kinase-mediated Ga2+ sensitization in the bovine cerebral artery: unimportant role for protein kinase C. Circ. Res. 91(2), 112-119 (2002). (Pubitemid 34827221)
28. Doran JD, Liu X, Taslimi P, Saadat A, Fox T. New insights into the structure-function relationships of Rho-associated kinase: a thermodynamic and hydrodynamic study of the dimer-to-monomer transition and its kinetic implications. Biochem. J. 384(Pt 2), 255-262 (2004). (Pubitemid 39656237)
29. Goleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane blebbing during apoptosis results from caspase- mediated activation of ROGK I. Nat. Cell. Biol. 3(4), 339-345 (2001). (Pubitemid 32288440)
30. Scbbagh M, Rcnvoizc G, Hamclin J, Riche N, Bcrtoglio J, Breard J. Gaspasc-3-mediated cleavage of ROGK I induces MLG phosphorylation and apoptotic membrane blebbing. Nat. Cell. Biol. 3(4), 346-352 (2001). (Pubitemid 32288441)
31. Scbbagh M, Hamclin J, Bcrtoglio J, Solary E, Breard J. Direct cleavage of ROGK II by granzymc B induces target cell membrane blebbing in a caspasc-indcpcndcnt manner. J. Exp. Med. 201 (3), 465-471 (2005). (Pubitemid 40229420)
32. Amano M, Ito M, Kimura K, et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinasc). J. Biol. Chem. 271(34), 20246-20249 (1996). (Pubitemid 26281788)
33. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (r-kinasc). Science 273(5272), 245-248 (1996). (Pubitemid 26285892)
34. Kawano Y, Fukata Y, Oshiro N, et al. Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinasc in vivo. J. Cell. Biol. 147(5), 1023-1038 (1999).
35. Kurcishi Y, Kobayashi S, Amano M, et al. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J. Biol. Chem. 272(19), 12257-12260 (1997). (Pubitemid 27203307)
36. Mackawa M, Ishizaki T, Boku S, et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROGK and LIM-kinasc. Science 285(5429), 895-898 (1999). (Pubitemid 29381991)
37. Ohashi K, Nagata K, Mackawa M, Ishizaki T, Narumiya S, Mizuno K. Rho-associated kinase ROGK activates LIM-kinasc 1 by phosphorylation at threonine 508 within the activation loop. J. Biol. Chem. 275(5), 3577-3582 (2000). (Pubitemid 30083067)
38. Sumi T, Matsumoto K, Nakamura T. Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROGK, a Rho-dependent protein kinase. J. Biol. Chem. 276(1), 670-676 (2001). (Pubitemid 32050364)
39. Amano T, Tanabe K, Eto T, Narumiya S, Mizuno K. LIM-kinasc 2 induces formation of stress fibres, focal adhesions and membrane blebs, dependent on its activation by Rho-associated kinasc-catalyscd phosphorylation at threonine-505. Biochem. J. 354(Pt 1), 149-159 (2001). (Pubitemid 32183455)
40. Lin T, Zeng L, Liu Y, DeFea K, et al. Rho-ROGK-LIMK-cofilin pathway regulates shear stress activation of sterol regulatory element bindingproteins. Circ. Res. 92(12), 1296-1304 (2003). (Pubitemid 36773471)
41. Matsui T, Maeda M, Doi Y ,et al. Rho-kinasc phosphorylates GOOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J. Cell. Biol. 140(3), 647-657 (1998). (Pubitemid 28134067)
42. Fukata Y, Oshiro N, KinoshitaN, et al. Phosphorylation of adducin by Rho-kinasc plays a crucial role in cell motility. J. Cell. Biol. 145(2), 347-361 (1999). (Pubitemid 29198306)
43. Hartshornc DJ. Myosin phosphatase: subunits and interactions. Acta. Phydol. Scand. 164(4), 483-493 (1998).
44. Rikitakc Y, Liao JK. ROCKs as therapeutic targets in cardiovascular diseases. Expert Rev. Cardiovasc. Ther. 3(3), 441-451 (2005). (Pubitemid 40691914)
45. Wirth A. Rho kinase and hypertension. Biochim. Biophys. Acta. 1802(12), 1276-1284 (2010).
46. Sotiropoulos A, Gincitis D, Copcland J, Treisman R. Signal-regulated activation of scrum response factor is mediated by changes in actin dynamics. Cell 98(2), 159-169 (1999). (Pubitemid 29344904)
47. Posern G, Treisman R. Actin' together: scrum response factor, its cofactors and the link to signal transduction. Trends Cell. Biol. 16(11), 588-596 (2006). (Pubitemid 44636222)
48. Miralles F, Posern G, Zaromytidou Al, Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 113(3), 329-342 (2003). (Pubitemid 36556115)
49. Vartiainen MK, Guettler S, Larijani B, Treisman R. Nuclear actin regulates dynamic subcellular localization and activity of the SRF cofactor MAL. Science 316(5832), 1749-1752 (2007). (Pubitemid 46988550)
50. Wang D, Chang PS, Wang Z, et al. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for scrum response factor. Cell 105(7), 851-862 (2001). (Pubitemid 32635087)
51. Wang DZ, Li S, Hockcmeyer D, et al. Potentiation of scrum response factor activity by a family of myocardin-rclatcd transcription factors. Proc. Natl Acad. Sci. USA 99(23), 14855-14860 (2002). (Pubitemid 35334573)
52. Olson EN, Nordhcim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat. Rev. Mol. Cell. Biol. 11(5), 353-365 (2010).
53. Small EM, Thatcher JE, Sutherland LB, et al. Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction. Circ. Res. 107(2), 294-304 (2010).
54. Ishiko K, Sakoda T, Akagami T, et al. Hyperglycemia induced cell growth and gene expression via the scrum response clement through RhoA and Rho-kinasc in vascular smooth muscle cells. Prep. Biochem. Biolechnol. 40(2), 139-151 (2010).
55. Li Z, Dong X, Wang Z, et al. Regulation of PTEN by Rho small GTPases. Nat. Cell. Biol. 7(4), 399-404 (2005). (Pubitemid 40533130)
56. Chang J, Xic M, Shah VR, et al. Activation of Rho-associated coilcd-coil protein kinase 1 (ROCK-1) by caspasc-3 clcavagc plays an essential role in cardiac myocytc apoptosis. Proc. Natl Acad. Set. USA 103(39), 14495-14500 (2006). (Pubitemid 44484778)
57. Vcmula S, Shi JJ, Hanncman P, Wei L, Kapur R. ROCK1 functions as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. Blood 115(9), 1785-1796 (2010).
58. Begum N, Sandu OA, Ito M, Lohmann SM, Smolcnski A. Activc Rho kinase (ROK-a ) associates with insulin receptor substratc-1 and inhibits insulin signaling in vascular smooth muscle cells. J. Biol. Chem. 277(8), 6214-6222 (2002). (Pubitemid 34968412)
59. Lim MJ, Choi KJ, Ding Y, et al. RhoA/Rho kinase blocks muscle differentiation via serine phosphorylation of insulin receptor substratc-1 and -2. Mol. Endocrinol. 21(9), 2282-2293 (2007). (Pubitemid 47347388)
60. Farah S, Agazic Y, Ohan N, Ngsce JK, Liu XJ. A Rho-associated protein kinase, ROKa, binds insulin receptor substratc-1 and modulates insulin signaling. J. Biol. Chem. 273(8), 4740-4746 (1998). (Pubitemid 28103223)
61. Furukawa N, Ongusaha P, Jahng WJ, et al. Role of Rho-kinasc in regulation of insulin action and glucose homeostasis. Cell. Melab. 2(2), 119-129 (2005).
62. Kanda T, Wakino S, Homma K, et al. Rho-kinasc as a molecular target for insulin resistance and hypertension. FASEBJ. 20(1), 169-171 (2006). (Pubitemid 43100503)
63. Lee DH, Shi J, Jcoung NH, et al. Targeted disruption of ROCKl causes insulin resistance in vivo. J. Biol. Chem. 284(18), 11776-11780 (2009).
64. Wang Y, Zheng XR, Riddick N, et al. ROCK isoform regulation of myosin phosphatase and contractility in vascular smooth muscle cells. Circ. Res. 104(4), 531-540 (2009).
65. Yoneda A, Multhaupt HA, Couchman JR. The Rho kinases I and II regulate different aspects of myosin II activity. J. Cell. Biol. 170(3), 443-453 (2005). (Pubitemid 41126943)
66. Yoneda A, Ushakov D, Multhaup t HA, Couchman JR. Fibronectin matrix assembly requires distinct contributions from Rho kinases I and -II. Mol. Biol. Cell. 18(1), 66-75 (2007). (Pubitemid 46066711)
67. Noguchi M, Hosoda K, Fujikura J, et al. Genetic and pharmacological inhibition of Rho-associated kinase II enhances adipogcncsis. J. Biol. Chem. 282(40), 29574-29583 (2007). (Pubitemid 350043374)
68. Mong PY, Wang Q. Activation of Rho kinase isoforms in lung endothelial cells during inflammation. J. Immunol. 182(4), 2385-2394 (2009).
69. Bryan BA, DcnnstcdtE, Mitchell DC, et al. RhoA/ROCK signaling is essential for multiple aspects ofVEGF-mcdiatcd angiogcncsis. FASEB J. 24(9), 3186-3195 (2010).
70. Shimada H, Rajagopalan LE. Rho kinasc-2 activation in human endothelial cells drives lysophosphatidic acid-mediated expression of cell adhesion molecules via NF-KB p65. J. Biol. Chem. 285(17), 12536-12542 (2010).
71. Lock FE, Hotchin NA. Distinct roles for ROCK1 and ROCK2 in the regulation of kcratinocytc differentiation. PloS ONE 4(12), c8190 (2009).
72. Inaba N, Ishizawa S, Kimura M, et al. Effect of inhibition of the ROCK isoform on RT2 malignant glioma cells. Anticancer Res. 30(9), 3509-3514 (2010).
73. Shi J, Zhang L, Wei L. Rho-kinasc in development and heart failure: insights from genetic models. Pedialr. Cardiol. 32(3), 297-304 (2011).
74. Shimizu Y, Thumkco D, Keel J, et al. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J. Cell. Biol. 168(6), 941-953 (2005). (Pubitemid 40397008)
75. Rikitakc Y, Oyama N, Wang CY, et al. Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficicnt mice. Circulation 112(19), 2959-2965 (2005). (Pubitemid 41612298)
76. Zhang YM, Bo J, Taffet GE, et al. Targeted deletion ofROCKl protects the heart against pressure overload by inhibiting reactive fibrosis. FASEB J. 20(7), 916-925 (2006). (Pubitemid 44943949)
77. Thumkco D, Keel J, Ishizaki T, et al. Targeted disruption of the mouse Rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol. Cell. Biol. 23(14), 5043-5055 (2003). (Pubitemid 36793348)
78. Thumkco D, Shimizu Y, Sakamoto S, Yamada S, Narumiya S. ROCK-I and ROCK-II cooperatively regulate closure of eyelid and ventral body wall in mouse embryo. Genes Cells 10(8), 825-834 (2005). (Pubitemid 41158741)
79. Duffy P, Schmandkc A, Schmandkc A, et al. Rho-associated kinase II (ROCKII) limits axonal growth after trauma within the adult mouse spinal cord.J. Neurosci. 29(48), 15266-15276 (2009).
80. Zhou Z, Meng Y, Asrar S, Todorovski Z, Jia Z. A critical role of Rho-kinasc ROCK2 in the regulation of spine and synaptic function. Neuropharmacology 56(1), 81-89 (2009).
81. Hoshijima M, Sah VP, Wang Y, Chicn KR, Brown JH. The low molccular weight GTPasc Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho kinase. J. Biol. Chem. 273(13), 7725-7730 (1998). (Pubitemid 28152803)
82. Kuwahara K, Sairo Y, Nakagawa O, et al. The effects of the selective ROCK inhibitor, Y27632, on ET-l-induced hypertrophic response in neonatal rat cardiac myocytes - possible involvement of Rho/ROCK pathway in cardiac muscle cell hypertrophy. FEBS Lell. 452(3), 314-318 (1999). (Pubitemid 29301767)
83. Wei L. Lysophospholipid signaling in cardiac myocytc hypertrophy. J. Mol. Cell. Cardiol. 36(4), 465-468 (2004). (Pubitemid 38469937)
84. Yanazumc T, Hascgawa K, Wada H, et al. Rho/ROCK pathway contributes to the activation of cxtraccllular signal-regulated kinasc/GATA-4 during myocardial cell hypertrophy. J. Biol. Chem. 277(10), 8618-8625 (2002). (Pubitemid 34968328)
85. Brown JH, Del Rc DP, Sussman MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ. Res. 98(6), 730-742 (2006).
86. Yc Y, Hu SJ, Li L. Inhibition of farncsylpyrophosphatc synthase prevents angiotensin Il-induced hypertrophic responses in rat neonatal cardiomyocytes: involvement of the RhoA/Rho kinase pathway. FEBS Lell. 583(18), 2997-3003 (2009).
87. Hunter JC, Zcidan A, Javadov S, Kilic A, Rajapurohitam V, Karmazyn M. Nitric oxide inhibits cndothclin-l-induced neonatal cardiomyocyte hypertrophy via a RhoA-ROCK-dependent pathway. J. Mol. Cell. Cardiol. 47(6), 810-818 (2009).
88. Chorianopoulos E, Hcgcr T, Lutz M, et al. FGF-induciblc 14-kDa protein (Fnl4) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-icB activation by TWEAK. Basic Res. Cardiol. 105(2), 301-313 (2010).
89. Doi T, Sakoda T, Akagami T, et al. Aldosterone induces intcrlcukin-18 through cndothclin-1, angiotensin II, Rho/Rho- kinasc, and PPARs in cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 295(3), H1279-H1287 (2008).
90. Lee Y, Gustafsson AB. Role of apoptosis in cardiovascular disease. Apoptosis 14(4), 536-548 (2009).
91. Whclan RS, Kaplinskiy V, Kitsis RN. Ccll death in the pathogenesis of heart disease: mechanisms and significance. Ann. Rev. Physiol. 72, 19-44 (2010).
92. Dorn GW 2nd. Ap op to tic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc. Res. 81(3), 465-473 (2009).
93. Del Rc DP, Miyamoto S, Brown JH. RhoA/Rho kinase up-rcgulatc Bax to activate a mitochondrial death pathway and inducc cardiomyocyte apoptosis. J. Biol. Chem. 282(11), 8069-8078 (2007). (Pubitemid 47093605)
94. Del Rc DP, Miyamoto S, Brown JH. Focal adhesion kinase as a RhoA-activablc signaling scaffold mediating Akt activation and cardiomyocytc protection. J. Biol. Chem. 283(51), 35622-35629 (2008).
95. Shi J, Zhang YW, Yang Y, Zhang L, Wei L. ROCKl plays an essential role in the transition from cardiac hypertrophy to failure in mice./Mol. Cell. Cardiol. 49(5), 819-828 (2010).
96. Grimm M, Haas P, Willipinski-Stapclfcldt B, et al. Key role of myosin light chain (MLC) kinasc-mcdiatcd MLC2a phosphorylation in the a 1-adrenergic positive inotropic effect in human atrium. Cardiovasc. Res. 65(1), 211-220 (2005). (Pubitemid 40038494)
97. Rajashrcc R, Blunt BC, Hofmann PA. Modulation of myosin phosphatase targeting subunit and protein phosphatase 1 in the heart. Am. J. Physiol. Heart Circ. Physiol. 289(4), HI736-HI743 (2005).
98. Davis JS, Hassanzadch S, Winitsky S, et al. The overall pattern of cardiac contraction depends on a spatial gradient of myosin regulatory light chain phosphorylation. Cell 107(5), 631-641 (2001). (Pubitemid 34014864)
99. Vahcbi S, Kobayashi T, Warren CM, dc Tombc PP, Solaro RJ. Functional effects of Rho-kinasc-dcpcndent phosphorylation of specific sites on cardiac troponin. Circ. Res. 96(7), 740-747 (2005). (Pubitemid 40559513)
100. Lin G, Craig GP, Zhang L, et al. Acutc inhibition of Rho-kinasc improves cardiac contractile function in streptozotocin-diabetic rats. Cardiovasc. Res. 75(1), 51-58 (2007). (Pubitemid 46873512)
101. Stepanova OV, Chadin AV, Masiutin AG, et al. Rho-associated protein kinase is involved in establishing the contractile phenotype of cardiomyocy tcsl. Siofizika 55 (5), 880-885 (2010).
102. JacotJG, McCulloch AD, Omens JH. Substrate stiffness affccts the functional maturation of neonatal rat ventricular myocytes. Bioplrys. J. 95(7), 3479-3487 (2008).
103. Vlasblom R, Mullcr A, Beckers CM, et al. RhoA-ROCK signaling is involved in contraction-mediated inhibition of SERCA2a expression in cardiomyocytes. Pfiugers. Arch. 458(4), 785-793 (2009).
104. Narumiya S, Ishizaki T, Uchata M. Use and properties of ROCK-spccific inhibitor Y-27632. Methods Enzymol. 325, 273-284 (2000).
105. Olson MF. Applications for ROCK kinase inhibition. Curr. Opin. Cell. Biol. 20(2), 242-248 (2008).
106. Davics SP, Rcddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351(Pt 1), 95-105 (2000).
107. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408(3), 297-315 (2007).
108. Liao JK, Scto M, Noma K. Rho kinase (ROCK) inhibitors.J. Cardiovasc. Pharmacol. 50(1), 17-24 (2007).
109. Lohn M, Plcttcnburg O, Ivashchcnko Y, et al. Pharmacological charactcrization of SAR407899, a novel Rho-kinasc inhibitor. Hypertension 54(3), 676-683 (2009).
110. Kast R, Schirok H, Figucroa-Pcrcz S, et al. Cardiovascular effects of a novel potent and highly selective azaindolc-bascd inhibitor of Rho-kinasc. Br. J. Pharmacol. 152(7), 1070-1080 (2007). (Pubitemid 350166052)
111. Doe C, Bentlcy R, Bchm DJ, et al. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J. Pharmacol. Exp. Ther. 320(1), 89-98 (2007). (Pubitemid 46025723)
112. Dhaliwal JS, Badejo AM Jr, Casey DB, Murthy SN, Kadowitz PJ. Analysis of pulmonary vasodilator responses to SB-772077-B [4-(7-((3-amino-l-pyrrolidinyl) carbonyl) -l-ethyl-lH-imidazo(4,5-c) pyridin- 2-yl)-l,2,5-oxadiazol-3-amincl, a novel aminofurazan-based Rho kinase inhibitor./Pharmacol. Exp. Ther. 330 (1), 334-341 (2009).
113. Boerma M, Fu Q, Wang J, et al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul. Fibrinolysis 19(7), 709-718 (2008).
114. Rawlings R, Nohria A, Liu IJY, et al. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on Rho kinase activity in Caucasian men with a previous atherosclerotic event. Am. J. Cardiol. 103(4), 437-441 (2009).
115. Kobayashi N, Takcshima H, Fukushima H, et al. Cardioprotective effects of pravastatin on cardiac performance and remodeling in failing rat hearts. Am. J. Hyperlens. 22(2), 176-182 (2009).
116. Kobayashi N, Ohno T, Yoshida K, et al. Cardioprotective mechanism of telmisartan via PPAR-y-cNOS pathway in dahl salt-sensitive hypertensive rats. Am. J. Hyperlens. 21(5), 576-581 (2008). (Pubitemid 351589680)
117. Zhou Q, Liao JK. Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr. Pbarm. Des. 15(27), 3108-3115 (2009).
118. Otsuka T, Ibuki C, Suzuki T, et al. Administration of the Rho-kinasc inhibitor, fasudil, following nitroglycerin additionally dilates the site of coronary spasm in patients with vasospastic angina. Coron. Arlery Dis. 19(2), 105-110 (2008). (Pubitemid 351317374)
119. Weir MR, Dzau VJ. The renin-angiotensin- aldostcronc system: a specific target for hypertension management. Am. J. Hyperlens. 12(12 Pt 3), 205S-213S (1999). (Pubitemid 30029273)
120. Schulz E, Gori T, MunzclT.Oxidative stress and endothelial dysfunction in hypertension. Hyperlens. Res. 34(6), 665-673 (2011).
121. Touyz RM, Schiffrin EL. Signal transduction mcchanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol. Rev. 52(4), 639-672 (2000).
122. dc Cavanagh EM, Fcrdcr M, Inscrra F, Fcrdcr L. Angiotensin II, mitochondria, cy toskclctal, and cxtraccllular matrix connections: an integrating viewpoint. Am. J. Physiol. Hearl Circ. Physiol. 296(3), H550-H558 (2009).
123. Gricndling KK, Sorcscu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86(5), 494-501 (2000). (Pubitemid 30165039)
124. Mukai Y, Shimokawa H, Matoba T, et al. Involvement of Rho-kinasc in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 15(6), 1062-1064 (2001).
125. Moriki N, Ito M, Scko T, et al. RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hyperlens. Res. 27(4), 263-270 (2004). (Pubitemid 38594398)
126. Scko T, Ito M, Kurcishi Y, et al. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ. Res. 92(4), 411-418(2003). (Pubitemid 36298201)
127. Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Sctoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 38 (6), 1307-1310 (2001). (Pubitemid 34033407)
128. ScasholtzTM, WcssclJ, Rao F, et al. Rho kinase polymorphism influcnccs blood pressure and systcmic vascular resistance in human twins: role ofhcrcdity. Hypertension 47(5), 937-947 (2006). (Pubitemid 44297566)
129. Rankincn T, Church T, Ricc T, Markward N, Blair SN, Bouchard C. A major haplotypc block at the Rho-associated kinase 2 locus is associated with a lower risk of hypertension in a rcccssivc manner: the HYPGENE study. Hyperlens. Res. 31(8), 1651-1657 (2008).
130. Sun Q, Yuc P, Ying Z, et al. Air pollution exposure potentiates hypertension through rcactivc oxygen spccics-mcdiatcd activation of Rho/ROCK. Arlerioscler. Thromb. Vase. Biol. 28(10), 1760-1766 (2008).
131. Guilluy C, Brcgcon J, Toumaniantz G, et al. The Rho exchange factor Arhgcfl mediates the effects of angiotensin II on vascular tone and blood pressure. Nat. Med. 16(2), 183-190 (2010).
132. Wirth A, Bcnyo Z, Lukasova M, et al. G12-G13-LARG-mcdiatcd signaling in vascular smooth muscle is required for salt-induced hypertension. Nat. Med. 14(1), 64-68 (2008).
133. Kataoka C, Egashira K, Inouc S, et al. Important role of Rho-kinasc in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 39(2), 245-250 (2002). (Pubitemid 34165223)
134. Hassona MD, Abouclnaga ZA, Elnakish MT, et al. Vascular hypertrophy-associated hypertension of profilinl transgenic mouse model leads to functional remodeling of peripheral arteries. Am. J. Physiol. Hearl Circ. Physiol. 298(6), H2112-H2120 (2010).
135. Takcda K, Ichiki T, Tokunou T, et al. Critical role of Rho-kinase and MEK/ERKpathways for angiotensin Il-induced plasminogen activator inhibitor type-1 gene expression. Arlerioscler. Thromb. Vase. Biol. 21(5), 868-873 (2001). (Pubitemid 32448782)
136. Rikitakc Y, LiaoJK. Rho-kinasc mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation 111(24), 3261-3268 (2005). (Pubitemid 40874999)
137. Funakoshi Y, Ichiki T, Shimokawa H, et al. Rho-kinase mediates angiotensin Il-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 38(1), 100-104 (2001). (Pubitemid 34224779)
138. Higashi M, Shimokawa H, Hattori T, et al. Long-term inhibition of Rho-kinase suppresses angiotensin Il-induced cardiovascular hypertrophy in rats in vivo-. effect on endothelial NAD(IJ)H oxidase system. Circ. Res. 93(8), 767-775 (2003). (Pubitemid 37288672)
139. Ito K, Hirooka Y, Sakai K, et al. Rho/Rho-kinasc pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mcchanisms of hypertension. Circ. Res. 92(12), 1337-1343 (2003). (Pubitemid 36773476)
140. Ito K, Hirooka Y, Kishi T, et al. Rho/Rho-kinasc pathway in the brainstem contributes to hypertension caused by chronic nitric oxide synthase inhibition. Hypertension 43(2), 156-162 (2004). (Pubitemid 38174167)
141. Ito K, Kimura Y, Hirooka Y, Sagara Y, Sunagawa K. Activation of Rho-kinase in the brainstem enhances sympathetic drive in mice with heart failure. Aulon. Neurosci. 142(1-2), 77-81 (2008).
142. Laufs U, LiaoJK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPasc. J. Biol. Chem. 273(37), 24266-24271 (1998). (Pubitemid 28435775)
143. Eto M, Barandicr C, Rathgcb L et al. Thrombin suppresses endothelial nitric oxide synthase and uprcgulatcs cndothclin- convcrting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activatcd protein kinase. Circ. Res. 89(7), 583-590 (2001). (Pubitemid 32924212)
144. Takcmoto M, Sun J, Hiroki J, Shimokawa H, LiaoJK. Rho-kinasc mediates hypoxia- induced downrcgulation of endothelial nitric oxide synthase. Circulation 106(1), 57-62 (2002). (Pubitemid 34747442)
145. Rikitakc Y, Kim HH, Huang Z, et al. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36(10), 2251-2227 (2005).
146. MingXF, Viswambharan H, Barandicr C, et al. Rho GTPasc/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol. Cell. Biol. 22(24), 8467-8477 (2002). (Pubitemid 35397163)
147. Wolfrum S, Dendorfer A, Rikitakc Y, et al. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinasc/protein kinase Akt and cardiovascular protection. Arlerioscler. Thromb. Vase. Biol. 24(10), 1842-1847 (2004). (Pubitemid 39350301)
148. + sensitization of contraction in vascular smooth muscle.J. Biol. Chem. 275(28), 21722-21729 (2000).
149. Noma K, Rikitakc Y, Oyama N, et al. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury.J. Clin. Invest. 118(5), 1632-1644 (2008). (Pubitemid 351632368)
150. Dong M, Yan BP, Yu CM. Current status of Rho-associated kinases (ROCKs) in coronary athcrosclcrosis and vasospasm. Cardiovasc. Hemalol. Agents Med. Chem. 7(4), 322-330 (2009).
151. Mori-Kawabc M, Tsushima H, Fujimoto S, Tada T, Ito J. Role of Rho/Rho-kinasc and NO/cGMP signaling pathways in vascular function prior to athcrosclcrosis. J. Alheroscler. Thromb. 16(6), 722-732 (2009).
152. Rckhtcr M, Chandrasckhar K, Gifford-Moorc D. et al. Immunohistochcmical
153. Wu DJ, Xu JZ, Wu YJ, et al. Effccts of fasudil on early athcrosclcrotic plaque formation and established lesion progression in apolipoprotcin E-knockout micc. Atherosclerosis 207(1), 68-73 (2009).
154. Wang HW, Liu PY, Oyama N, et al. Dcficicncy of ROCKl in bone marrow-derived cells protects against athcrosclcrosis in LDLR-/- micc. EASES J. 22(10), 3561-3570 (2008).
155. Bao W, Hu E, Tao L, et al. Inhibition of Rho-kinasc protects the heart against ischcmia/rcpcrfusion injury. Cardiovasc. Res. 61(3), 548-558 (2004). (Pubitemid 38210160)
156. Hamid SA, Bower HS, Baxter GF. Rho kinase activation plays a major role as a mediator of irreversible injury in rcpcrfuscd myocardium. Am. J. Physiol. Hearl Circ. Physiol. 292(6), H2598-H2606.
157. Zhang J, Li XX, Bian HJ, Liu XB, Ji XP, Zhang Y. Inhibition of the activity of Rho-kinasc rcduccs cardiomyocyte apoptosis in heart ischcmia/rcpcrfusion via suppressing JNK-mcdiatcd AIF translocation. Clin. Chim. Acta. 401(1-2), 76-80 (2009).
158. Shibata I, Yoshitomi O, Use T, et al. Administration of the Rho-kinasc inhibitor fasudil before ischemia or just after rcpcrfusion, but not 30 min after rcpcrfusion, protects the stunned myocardium in swine. Cardiovasc. Drugs Ther. 22(4), 293-298 (2008).
159. Gadctc VJ, Sawicka J, Polcwicz D, Doroszko A, Wozniak M, Sawicki G. Effect of the Rho kinase inhibitor Y-27632 on the protcomc of hearts with ischcmia-rcpcrfusion injury. Proleomics 10(24), 4377-4385 (2010).
160. Kobayashi M, Tanouc Y, Eto M et al. A Rho-kinasc inhibitor improves cardiac function after 24-hour heart preservation. J. Thorac. Cardiovasc. Surg. 136(6), 1586-1592 (2008).
161. Zhang J, Bian HJ, Li XX, et al. ERK-MAPK signaling opposes Rho-kinasc to reduce cardiomyocyte apoptosis in heart ischemic preconditioning. Mol. Med. 16(7-8), 307-315 (2010).
162. Zhao JL, Yang YJ, Pci WD, Sun YH, You SJ, Gao RL. Remote pcriconditioning rcduccs myocardial no-rcflow by the activation of K ATP channel via inhibition of Rho-kinasc. Inl.J. Cardiol. 133(2), 179-184 (2009).
163. Sakamoto K, Nakahara T, Ishii K. Rho-Rho kinase pathway is involved in the protective cffcct of early ischemic preconditioning in the rat heart. Biol. Pharm. Bull. 34(1), 156-159 (2011).
164. Dcmiryurck S, Kara AF, Cclik A, Babul A, Tarakcioglu M, Dcmiryurck AT. Effccts of fasudil, a Rho-kinasc inhibitor, on myocardial preconditioning in anesthetized rats. Eur. J. Pharmacol. 527(1-3), 129-140 (2005). (Pubitemid 41745160)
165. Haudck SB, Gupta D, Dcwald O, et al. Rho kinasc-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation. Cardiovasc. Res. 83(3), 511-518 (2009).
166. Hcinckc J, Molkcntin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell. Biol. 7(8), 589-600 (2006).
167. Hill JA, Olson EN. Cardiac plasticity. N. Engl. J. Med. 358(13), 1370-1380 (2008).
168. Satoh S, Ucda Y, Koyanagi M, et al. Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J. Mol. Cell. Cardiol. 35(1), 59-70 (2003). (Pubitemid 36286968)
169. Hattori T, Shimokawa H, Higashi M, et al. Long-term inhibition of Rho-kinasc suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 109(18), 2234-2239 (2004). (Pubitemid 38625402)
170. Kobayashi N, Horinaka S, Mita S, et al. Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc. Res. 55(4), 757-767 (2002).
171. Fukui S, Fukumoto Y, Suzuki J, et al. Long-term inhibition of Rho-kinasc ameliorates diastolic heart failure in hypertensive rats.J. Cardiovasc. Pharmacol. 51(3), 317-326 (2008).
172. Phrommintikul A, Tran L, Kompa A, et al. Effccts of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am. J. Physiol. Hean Circ. Physiol. 294(4), H1804-H1814 (2008). (Pubitemid 351490610)
173. Kagiyama S, Matsumura K, Goto K, Otsubo T, Iida M. Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type la receptor knockout micc. Regul. Pepi. 160(1-3), 133-139 (2010).
174. Ishimaru K, Ucno H, Kagitani S, Takabayashi D, Takata M, Inouc H. Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macroph age infiltration in the heart of DOCA/salt hypertensive rats./Cardiovasc. Pharmacol. 50(2), 187-194 (2007). (Pubitemid 47267744)
175. Shi J, Zhang YW, Summers LJ, Dorn GW 2nd, Wei L. Disruption of ROCKl gene attenuates cardiac dilation and improves contractilc function in pathological cardiac hypertrophy. J. Mol. Cell. Cardiol. 44(3), 551-560 (2008).
176. Fukumoto Y, MatobaT, Ito A, et al. Acutc vasodilator effects of a Rho-kinasc inhibitor, fasudil, in patients with severe pulmonary hypertension. Hearl9l(3), 391-392 (2005). (Pubitemid 40299237)
177. Ishikura K, Yamada N, Ito M et al. Beneficial acutc effects of Rho-kinasc inhibitor in patients with pulmonary arterial hypertension. Circ. J. 70(2), 174-178 (2006). (Pubitemid 43170128)
178. Guilluy C, Eddahibi S, Agard C, et al. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am. J. Respir. Cril. Care Med. 179(12), 1151-1158 (2009).
179. Doe Z, Fukumoto Y, Takaki A, et al. Evidence for Rho-kinasc activation in patients with pulmonary arterial hypertension. Circ. J. 73(9), 1731-1739 (2009).
180. Fujita H, Fukumoto Y, Saji K, et al. Acutc vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Hearl Vessels 25(2), 144-149 (2010).
181. Li F, Xia W, Yuan S, Sun R. Acutc inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease. Pedialr. Cardiol. 30(3), 363-366 (2009).
182. Nohria A, Grunert ME, Rikitakc Y, et al. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ. Res. 99(12), 1426-1432 (2006). (Pubitemid 44949679)
183. Masumoto A, Mohri M, Shimokawa H, Urakami L, Usui M, Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105(13), 1545-1547 (2002). (Pubitemid 34297629)
184. Mohri M, Shimokawa H, Hirakawa Y, Masumoto A, Takeshita A. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J. Am. Coll. Cardiol. 41(1), 15-19 (2003). (Pubitemid 36044397)
185. Inokuchi K, Ito A, Fukumoto Y, et al. Usefulness of fasudil, a Rho-kinasc inhibitor, to treat intractable severe coronary spasm after coronary artery bypass surgery./Cardiovasc. Pharmacol. 44(3), 275-277 (2004). (Pubitemid 39129443)
186. Disli OM, Ozdcmir E, Bcrkan O, Bagcivan I, Durmus N, Parlak A. Rho-kinasc inhibitors Y-27632 and fasudil prevent agonist-induced vasospasm in human radial artery. Can. J. Physiol. Pharmacol. 87(8), 595-601 (2009).
187. Noma K, Goto C, Nishioka K, et al. Roles of Rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness.J. Am. Coll. Cardiol. 49(6), 698-705 (2007). (Pubitemid 46205044)
188. Kishi T, Hirooka Y, Masumoto A, et al. Rho-kinasc inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 111(21), 2741-2747 (2005). (Pubitemid 40791544)
189. Shimokawa H, Hiramori K, Iinuma H, et al. Anti-anginal cffcct of fasudil, a Rho-kinasc inhibitor, in patients with stable effort angina: a multiccntcr study.J. Cardiovasc. Pharmacol. 40(5), 751-761 (2002). (Pubitemid 36109293)
190. Vicari RM, Chairman B, Kccfc D, et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placcbo- conrrollcd, Phase 2 trial. J. Am. Coll. Cardiol. 46(10), 1803-1811 (2005). (Pubitemid 41579800)
191. Fukumoto Y, Mohri M, Inokuchi K, et al. Anti-ischcmic effects of fasudil, a specific Rho-kinasc inhibitor, in patients with stable effort angina.J. Cardiovasc. Pharmacol. 49(3), 117-121 (2007). (Pubitemid 46579944)
192. Otsuka T, Ibuki C, Suzuki T, et al. Vasodilatory cffcct of subsequent administration of fasudil, a Rho-kinasc inhibitor, surpasses that of nitroglycerin at the conccntric coronary stenosis in patients with stable angina pectoris. Circ. J. 70(4), 402-408 (2006).
193. Nagata K, Kondoh Y, Satoh Y, et al. Effects of fasudil hydrochloride on ccrcbral blood flow in patients with chronic ccrcbral infarction. Clin. Neuropharmacol. 16(6), 501-510 (1993). (Pubitemid 23344762)
194. Busscmakcr E, Hcrbrig K, Pistrosch F, Palm C, Passaucr J. Role of Rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipients. Atherosclerosis 207(2), 567-572 (2009).
195. Nohria A, Prsic A, Liu PY, et al. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 205(2), 517-521 (2009).
196. Chan CK, Mak JC, Man RY, Vanhouttc PM. Rho kinase inhibitors prevent cndothclium- dependent contractions in the rat aorta. J. Pharmacol. Exp. Ther. 329(2), 820-826 (2009).
197. Casey DB, Badcjo AM, Dhaliwal JS, et al. Analysis of responses to the Rho-kinasc inhibitor Y-27632 in the pulmonary and systemic vascular bed of the rat. Am. j. Physiol. Hearl Circ. Physiol. 299(1), H184-H192 (2010).
198. Xu EZ, Kantorcs C, Ivanovska J, et al. Rescue treatment with a Rho-kinasc inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension. Am. j. Physiol. Hearl Circ. Physiol. 299(6), H1854-H1864 (2010).
199. van der Hcijden M, Verstcilen AM, Sipkema P, van Nicuw Amcrongcn GP, Musters RJ, Grocncvcld AB. Rho-kinasc-dcpcndcnt F-actin rearrangement is involved in the inhibition of PI3-kinasc/Akt during ischcmia-rcpcrfusion-induced endothelial cell apoptosis. Apoptosis 13(3), 404-412 (2008).